01:02 PM EDT, 03/23/2026 (MT Newswires) -- Gilead Sciences ( GILD ) is nearing an acquisition of autoimmune-disease-focused biotech Ouro Medicines for up to $2 billion, The Financial Times reported Monday, citing people familiar with the matter.

Under the terms being discussed, Gilead will pay Ouro Medicines' investors about $1.5 billion upfront in cash and an additional $500 million tied to certain clinical trial milestones, the report said.

Talks between the companies are at an advanced stage and a deal may be announced in the coming days, the report said.

Gilead Sciences ( GILD ) did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 137.02, Change: -0.19, Percent Change: -0.14